Detection of low-level tumor cells in allergic contact dermatitis induced by mechlorethamine in patients with mycosis fungoides.

Two patients with histologically proven mycosis fungoides, a malignancy of phenotypically mature T cells, received a topical challenge with mechlorethamine to areas of clinically uninvolved skin to exclude possible hypersensitivity reactions to this chemotherapeutic agent. In both patients, allergic contact dermatitis (ACD) developed at the sites of the application and resolved completely after withdrawal of mechlorethamine. The lesions were biopsied and analyzed for the presence of clonal T-cell receptor (TCR)-gamma gene rearrangements using two polymerase chain reaction (PCR)-based assays involving denaturing gradient gel electrophoresis (PCR/DGGE) and ribonuclease protection analysis (PCR/RPA). The former method has a clonal detection threshold of 10(-3)-10(-2), while the latter has a sensitivity of 10(-5). In both cases, the ACD lesions were polyclonal by PCR/DGGE. In contrast, PCR/RPA detected tumor-specific TCR-gamma gene rearrangements in these same lesions. This indicates that the ACD lesions contained tumor cells at a density within the 10(-5)-10(-2) range. Analysis of peripheral blood mononuclear cells from both patients failed to detect the malignant clone and showed the same result as blood from four normal individuals. The normal skin from one skin patient also lacked detectable TCR-gamma gene rearrangements. These results indicate that mycosis fungoides tumor are present within ACD lesions induced in mycosis fungoides patients and that this phenomenon does not appear to be due to the ubiquitous presence of detectable levels of these tumor cells in the blood or skin. These findings might be explained by nonspecific recruitment of malignant T cells to sites of local inflammation mediated by non-neoplastic antigen-specific T cells. Alternatively, they might be due to the local proliferation of very rare tumor cells in apparently normal skin in response to cytokines generated during the ACD reaction. In either case, the present study offers evidence that the malignant cells in myosis fungoides retain at least some capability of responding in vivo to physiologic stimuli.

[1]  J. Sklar,et al.  Molecular staging of cutaneous T-cell lymphoma: evidence for systemic involvement in early disease. , 1995, The Journal of investigative dermatology.

[2]  J. Sklar,et al.  Detection of clonal T-cell receptor gamma gene rearrangements in early mycosis fungoides/Sezary syndrome by polymerase chain reaction and denaturing gradient gel electrophoresis (PCR/DGGE). , 1994, The Journal of investigative dermatology.

[3]  W. Sterry,et al.  Clonal disease in early cutaneous T-cell lymphoma. , 1994, Dermatologic clinics.

[4]  L. Picker,et al.  Skin-selective lymphocyte homing mechanisms in the pathogenesis of leukemic cutaneous T-cell lymphoma. , 1993, The Journal of investigative dermatology.

[5]  J. Sklar,et al.  Quantitation of T-cell DNA in cutaneous lymphoid infiltrates. , 1991, The American journal of pathology.

[6]  K. L. Johnson,et al.  Enrichment and function of urushiol (poison ivy)-specific T lymphocytes in lesions of allergic contact dermatitis to urushiol. , 1990, Journal of immunology.

[7]  E. V. Van Scott,et al.  Long-term efficacy, curative potential, and carcinogenicity of topical mechlorethamine chemotherapy in cutaneous T cell lymphoma. , 1989, Journal of the American Academy of Dermatology.

[8]  D. Ramsay,et al.  Topical mechlorethamine therapy for early stage mycosis fungoides. , 1988, Journal of the American Academy of Dermatology.

[9]  E. Vonderheid,et al.  Topical Mechlorethamine Chemotherapy , 1984, International journal of dermatology.

[10]  R. Hoppe,et al.  Ointment‐based mechlorethamine treatment for mycosis fungoides , 1983, Cancer.

[11]  Z. Fuks,et al.  Topical mechlorethamine therapy for mycosis fungoides , 1977, The British journal of dermatology.

[12]  Z. Fuks,et al.  Mechlorethamine desensitization in therapy for mycosis fungoides. Topical desensitization to mechlorethamine (nitrogen mustard) contact hypersensitivity. , 1975, Archives of dermatology.

[13]  E. V. Van Scott,et al.  Complete remissions of mycosis fungoides lymphoma induced by topical nitrogen mustard (HN2). Control of delayed hypersensitivity to HN2 by desensitization and by induction of specific immunologic tolerance , 1973, Cancer.

[14]  E. V. Van Scott,et al.  Cutaneous hypersensitivity and desensitization to mechlorethamine in patients with mycosis fungoides lymphoma. , 1967, Annals of internal medicine.

[15]  J. Haserick,et al.  Remission of Lesions in Mycosis Fungoides Following Topical Application of Nitrogen Mustard: A Case Report , 1959 .